Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-Hour IOP Control in Ocular Hypertension: Inflow vs Outflow Drugs
NCT01655758Phase 4Completed
- Sponsor
- University of Parma
- Start
- Jan 2002
- Primary completion
- Dec 2003
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Timacor, dorzolamide, latanoprost, travoprost and bimatoprost in ocular hypertension, sponsored by University of Parma. Primary endpoint: Change in Mean Intraocular Pressure at Day 540. Started Jan 2002; status: completed.
02
Drugs
Timacordorzolamidelatanoprosttravoprostbimatoprost
03
Conditions
ocular hypertension
Beyond the preview
Go deeper on NCT01655758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01655758.